Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Revenue (2023 - 2025)

Historic Revenue for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to $1.6 million.

  • Entrada Therapeutics' Revenue fell 9175.27% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.5 million, marking a year-over-year decrease of 7141.69%. This contributed to the annual value of $210.8 million for FY2024, which is 6338.04% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Revenue stood at $1.6 million, which was down 9175.27% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Revenue registered a high of $94.7 million during Q2 2024, and its lowest value of $1.6 million during Q3 2025.
  • In the last 3 years, Entrada Therapeutics' Revenue had a median value of $25.3 million in 2023 and averaged $33.1 million.
  • In the last 5 years, Entrada Therapeutics' Revenue skyrocketed by 42115.58% in 2024 and then tumbled by 9794.07% in 2025.
  • Quarter analysis of 3 years shows Entrada Therapeutics' Revenue stood at $41.8 million in 2023, then dropped by 10.63% to $37.4 million in 2024, then tumbled by 95.68% to $1.6 million in 2025.
  • Its Revenue stands at $1.6 million for Q3 2025, versus $2.0 million for Q2 2025 and $20.6 million for Q1 2025.